We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





J&J’s Janssen Partners with BioSymetrics for Predicting Onset and Severity of COVID-19 Using Machine Learning

By HospiMedica International staff writers
Posted on 20 Aug 2020
Print article
Illustration
Illustration
Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceuticals Inc. (Beerse, Belgium) has entered into a collaboration with BioSymetrics Inc. (New York, NY, USA) and Sema4 (Stamford, CT, USA) that will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.

As part of the collaboration, the parties will use BioSymetrics' Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease. BioSymetrics, a biomedical artificial intelligence company that provides clinical insights and helps researchers develop drugs with greater speed and precision, has developed the platform based on a patent pending AI iteration framework that can be used in conjunction with clinical research to predict target mechanism, identify lead compounds, or provide clinical insights. The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against SARS-CoV-2.

"We've been working on deploying AI in the clinical setting for several years," said Anthony Iacovone, Co-Founder and Chairman of BioSymetrics. "We've demonstrated that machine learning can bring speed and precision to helping identify at risk patient populations, predict disease outcomes, and build better treatments, but the pandemic has now pushed biomedical AI technology to the fore front of innovative necessity."

"There is dramatic heterogeneity within the COVID-19 patient groups and a spectrum of disease risk that must be interpreted probabilistically – something of which I believe this collaboration will drive through innovation and combined expertise," added Eric Schadt, Founder and CEO of Sema4, a patient-centered health intelligence company.

Related Links:

BioSymetrics Inc.
Sema4
Johnson & Johnson
Janssen Pharmaceuticals Inc.
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Display
i3 Series

Print article

Channels

Critical Care

view channel
Image: The therapeutic tool can be used for children with kidney issues stemming from sepsis (Photo courtesy of 123RF)

New Device Treats Acute Kidney Injury from Sepsis

Sepsis, commonly referred to as "blood poisoning," can occur due to any infectious agent, triggering a systemic response by the body to combat the infection. This response involves the activation of circulating... Read more

Surgical Techniques

view channel
Image: The endoscopic device can 3D image the stiffness of individual biological cells and complex organisms (Photo courtesy of University of Nottingham)

World’s First Microscopic Probe to Revolutionize Early Cancer Diagnosis

In the early stages of cancer, the cells are significantly softer than normal cells, which facilitates their movement through small spaces and contributes to the rapid spread of the disease, a process... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.